Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy

Status unconfirmed · Phase 3

Conditions studied: Prostate Cancer

In brief

To asess the efficacy of Uroxatrol, an alpha blocker in men undergoing prostate brachytherapy to treat prostate cancer, and whether the use of Uroxatrol in advance of the brachytherapy is better or not than starting it on the day of surgery.

Key facts

Study ID

NCT00201630

Run by

New York Prostate Institute

People needed

150

Starts

2005-09-01

Expected to finish

2005-09-01

Last updated by the study team

2005-09-20

Who can join

Age: any. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• 1) Informed consent must be obtained. 2) Men of any age 3) Diagnosis of prostate cancer that is clinically localized 4) Patients must be eligible for permanent prostate brachytherapy either alone or with combination of other treatments (i.e. External beam radiation or hormonal therapy)

You may not qualify if…

• Refusal to participate in the study
• Prior use of alpha-blocker or anti-cholinergic medication in the treatment of prostate hypertrophy.
• Contraindication to using an alpha-blocker

Where it is running

• New York Prostate Institute — Oceanside, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.